3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Completed
5
Active not recruiting
3
Recruiting
2
Withdrawn
1
Enrolling by invitation
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Dermatologic
2
Conditions
Breast Neoplasms
1324
Neoplasms
982
Carcinoma, Non-Small-Cell Lung
860
Prostatic Neoplasms
724
Colorectal Neoplasms
666
Lung Neoplasms
551
Leukemia, Myeloid, Acute
475
Neoplasm Metastasis
434
Pancreatic Neoplasms
419
Carcinoma, Hepatocellular
407
Multiple Myeloma
396
Ovarian Neoplasms
392
Stomach Neoplasms
379
Recurrence
364
Squamous Cell Carcinoma of Head and Neck
325
Melanoma
294
Brain Neoplasms
287
Uterine Cervical Neoplasms
283
Triple Negative Breast Neoplasms
271
Glioblastoma
264
Head and Neck Neoplasms
263
Precursor Cell Lymphoblastic Leukemia-Lymphoma
254
Endometrial Neoplasms
234
Lymphoma
228
Rectal Neoplasms
222
Esophageal Neoplasms
222
Sarcoma
213
Carcinoma, Renal Cell
203
Colonic Neoplasms
194
Lymphoma, Non-Hodgkin
191
Interventions
relatlimab
1
pembrolizumab
1
lifileucel
1
Temozolomide
1
Paclitaxel
1
Opdualag
1
Nivolumab
1
Ipilimumab
1
Eye Movement Desensitization Reprocessing
1
Dacarbazine
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Interventional
×
Melanoma, Cutaneous Malignant
×
Clear all
NCT06743126
2026-05-29
SUPRAME
Immatics US, Inc.
Phase 3
Recruiting
360 enrolled
NCT06767332
2025-01-09
FAME
Leiden University Medical Center
Phase NA
Recruiting
30 enrolled